Onkos Surgical has expanded its paediatric musculoskeletal oncology portfolio with the introduction of the new JTS Extendible Prosthesis implant for paediatric bone cancer patients.
Leveraging magnetic technology, the device expands non-invasively for accommodating the natural growth curve of patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The device preserves lower limb length equality for young patients with bone loss that occurs due to cancer.
Onkos founder and CEO Patrick Treacy said: “Paediatric sarcoma patients, who are candidates for the JTS growing prosthesis, often have complex treatment cycles in which we need to deliver precision designs in a very specific treatment window.
“Our investment in manufacturing innovation and design expertise will make a big difference in the future for these surgeons, patients and families and we couldn’t be more proud to serve their needs.”
The company has also unveiled its new modern manufacturing and R&D innovation centre at its headquarters in Parsippany, New Jersey, US. It will use this new facility for the integration and growth of the technology.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOnkos Manufacturing vice-president Gary Thomas said: “The new manufacturing facility and innovation centre will enable a more agile production environment and provide a world-class experience for our customers.
“Everything about the design of the facility is geared toward increasing speed, capacity and ownership of the supply chain to optimise our ability to deliver personalised devices.”
